作者: Christiane Adjé , Rachanee Cheingsong , Thierry H. Roels , Chantal Maurice , Gaston Djomand
DOI: 10.1097/00126334-200104150-00018
关键词:
摘要: To describe prevalence of antiretroviral (ARV) drug-resistant HIV-1 strains among patients with a history earlier treatment ARV drugs in Abidjan, Cote d'Ivoire, we determined mutations that confer drug resistance by sequencing the viral reverse-transcriptase and protease genes derived from plasma RNA 68 individuals consecutively enrolled Joint United Nations Program on AIDS Drug Access Initiative (UNAIDS-DAI) Abidjan between August 1998 April 1999. Phenotypic was assessed using recombinant virus assay. Primary associated to at least one inhibitors or were detected 39 (57.4%) patients. The was: 29 (42.6%) zidovudine, 10 (14.7%) lamivudine, (1.5%) didanosine, K103N mutation (associated delavirdine, nevirapine, efavirenz), Y181C delavirdine nevirapine), two both indinavir (M46I/L V82A) saquinavir (G48V L90M), each ritonavir (V82A) nelfinavir (D30N). nucleoside reverse transcriptase inhibitor (RTI) seen 25 (39.7%) patients, nonnucleoside RTIs 5 (8%) 4 (6%) high observed this study may limit future effectiveness programs d'Ivoire.